United States Patent 11,608,343: Scope and Claims Analysis, Coverage Boundaries, and US Patent Landscape
What does US Patent 11,608,343 claim, and how broad is Formula (I) coverage?
US 11,608,343 claim scope centers on a genus compound defined by Formula (I) plus salts and stereoisomers, with a structure-rugged core built from substitutable fragments (R1, R2, R3, R4, Z, R5) and a presence requirement that at least one of R1 and R2 is not H.
Core structural logic of claim 1 (genus)
Claim 1 defines:
- Compound: “A compound of Formula (I) … or a pharmaceutically acceptable salt or stereoisomer thereof”
- R1 (terminal substituent options): H, halogen, CH3, C≡CH, or OCH3
- R2: H or halogen
- R3: one of formula (i.1), (i.2), (i.3), (i.4)
- R4: one of R4.a or R4.b
- Q: a 4- to 6-membered heterocyclyl with one nitrogen atom, optionally one carbon atom substituted with CH3
- Z: a 4- to 6-membered heterocyclyl with one nitrogen atom, optionally one carbon atom substituted with CH3
- R5: H or CH3
- Proviso: at least one of R1 and R2 is not H
Practical breadth impact:
This is a classic “genus of substituent-permitted scaffolds” claim. It is broad in that it covers multiple heterocycle identities (via Q and Z frameworks), multiple substitution patterns (via optional CH3), multiple terminal groups (R1), and multiple ring/graft options for R3 and R4.
How the dependent claims narrow (claims 2-10)
Claims 2-10 set preferred/explicit embodiments of the same Formula (I) genus:
- Claim 2: R1 is halogen, CH3, C≡CH, or OCH3 (excludes R1=H)
- Claim 3: R1=F
- Claim 4: R1=Cl
- Claim 5: R1=CH3
- Claim 6: R1=C≡CH
- Claim 7: R1=OCH3
- Claim 8: R2=H
- Claim 9: R2=Cl
- Claim 10: specifies the internal definition of R4 via subclasses:
- R4.a via R4.a.1 with R6, m, n constraints
- R4.b via R4.b.1 with p, q constraints
Practical breadth impact:
Dependent claims don’t replace the genus; they add coverage granularity for examiners/litigators. They also matter for non-infringement: a competitor that stays in the genus but avoids the specific disclosed sub-classes can still infringe claim 1, unless validity or claim construction limits the genus scope.
Claims 11 and 15-34: “selected compounds” and structure-specific fallbacks
- Claim 11 provides a selection list (“selected from the group consisting of …”), but the text you provided omits the specific list entries (the “or a pharmaceutically acceptable salt thereof” is present without the enumerated structures).
- Claims 15-34 each state a “compound having the following structure: … or a pharmaceutically acceptable salt thereof,” again with the actual drawn structures omitted from the text you provided.
Practical breadth impact:
Structure-specific claims are usually narrower but stronger for infringement-to-enable mapping. They also function as fallback positions if the genus (claim 1) faces validity pressure.
How does the proviso “at least one of R1 and R2 is not H” affect infringement risk?
The proviso is a hard eligibility constraint:
- If a competitor’s compound has R1 = H and R2 = H, it falls outside the claim.
- If either:
- R1 is non-H (halogen, CH3, C≡CH, or OCH3), or
- R2 is non-H (halogen),
then the proviso is satisfied.
Infringement mapping implication:
The proviso narrows the genus by excluding the “fully unsubstituted” edge-case in which both terminal sites are hydrogen. For a competitor, this creates a clear design-around option if synthetic targets allow that substitution pattern.
What cancers are covered by the method-of-use claim (claim 14)?
Claim 14 is the only explicit method-of-treatment claim:
- “A method for treating cancer … administering … a compound according to claim 1 …”
- Cancer list (group consisting of):
- biliary, bladder, brain, breast, cervical, colorectal, endometrial, esophagus, gallbladder
- gastrointestinal, head and neck, kidney, liver, lung, prostate, skin
- plus “brain cancer” explicitly
Coverage boundary:
Because it is a method-of-use claim, infringement depends on:
- the administered product falling within claim 1 (or a salt/stereoisomer within it), and
- the use being within the enumerated cancer group.
Design-around implication:
A competitor cannot evade infringement solely by changing dosage form if the same active falls within claim 1 and is used for one of the listed cancers. To avoid claim 14, they’d need to either:
- use a compound outside claim 1’s Formula (I) coverage, or
- use for a cancer indication not in the enumerated list (if legally relevant to the claim structure).
What is covered by the composition claims (claims 12-13)?
- Claim 12: pharmaceutical composition with excipients and a therapeutically effective amount of the claim 1 compound.
- Claim 13: composition plus a second “therapeutically active substance” selected from:
- cytostatic active substance and
- cytotoxic active substance
Coverage boundary:
These are broad composition claims. They typically cover:
- mixtures where the claimed active is present in a therapeutically effective amount,
- with general excipients and co-actives constrained only by broad functional classes (cytostatic/cytotoxic).
Design-around implication:
Switching excipients does not avoid claim 12. Avoidance of claim 13 depends on whether the co-administered active falls within the broad cytostatic/cytotoxic classes and whether the claim is interpreted as requiring a specific co-formulation/composition (not just a combination therapy in general).
How strong is the patent estate likely to be based on claim architecture (genus + dependent + structure-specific)?
Even without the specification text, the claim architecture indicates a layered protection strategy:
- Broad genus (claim 1) with substituent permutations (R1, R2, R3, R4, Q, Z, R5).
- Multiple dependent embodiments (claims 2-10) to lock in common substitutions (F, Cl, CH3, C≡CH, OCH3; R2=Cl).
- Fallback enumerations (claim 11) and explicit structures (claims 15-34) that can preserve infringement coverage even if the genus narrows.
For litigation, this tends to:
- increase the chance that at least one claim remains infringed by an accused product,
- increase settlement leverage if any member of the competitor portfolio lines up with the explicit structures.
What does the Formula (I) structure suggest about novelty and potential invalidity angles?
The claim is built from:
- a defined heterocycle architecture (Q and Z each: 4-6 membered, one N, optionally CH3 on a carbon),
- substituent sets at R1/R2 (including halo, alkyl, alkynyl, methoxy),
- enumerated options for internal substituent frameworks (R3 via i.1-i.4; R4 via a/b subclasses with further parameterization).
Typical invalidity risks for this kind of genus claim:
- Enablement/breadth mismatch: if the spec does not teach how to make and use the full sweep of Q/Z/R3/R4/R1/R2 combinations, the genus may be challenged for insufficient written description or enablement.
- Obviousness over prior art scaffolds: if prior art discloses closely related heterocycles and substituent permutations, the “genus” may be argued as predictable optimization.
- Indefiniteness/claim construction disputes: parameterized substituents (R4.a.1 with m/n and p/q ranges; R3 i.1-i.4; “wherein the 4- to 6-membered heterocyclyl contains one nitrogen heteroatom”) can create claim-scope disputes if the definitions depend on drawings not in the claim text.
Those risks hinge on the specification and prosecution history, which are not included in the text you provided.
What adjacent patent landscape would typically surround US 11,608,343 (and how to map it)?
Your prompt specifies only claim text and patent number, but not:
- publication/application number(s),
- assignee,
- priority filings,
- family members,
- or the Orange Book/bio-related context.
Without those concrete bibliographic and legal records, a complete US landscape build cannot be produced to required standards for business decisions.
What can be concluded from the claims alone:
US 11,608,343 is almost certainly part of an invention family that protects:
- a scaffold defined by Formula (I),
- specific sub-classes of substituents (R1 variants and R4 subclasses),
- enumerated compounds (claim 11),
- composition (claims 12-13),
- and at least one oncology indication set (claim 14).
That usually correlates with co-pending related US applications in the same family that cover:
- alternate stereochemistry,
- crystalline forms,
- additional formulations/dosage regimens,
- and combination regimens.
A defensible landscape requires the missing family/patent record.
How many claims meaningfully affect competitors: only claim 1, or also dependent/composition/method?
From a freedom-to-operate perspective, the practical infringement surface is broad:
- Claim 1 is the main hook.
- Claims 2-10 add redundancy around common substituent picks. A competitor copying R1/R2 selections that match these dependent claims is more clearly within the genus.
- Claims 12-13 capture formulation and combination-product scenarios.
- Claim 14 captures oncology indication use (method-of-use). Even if a competitor’s product is the same active, off-indication use may fall outside claim 14.
The structure-specific claims 15-34 (without seeing the enumerated drawings) usually become pivotal in litigation because they can be asserted as alternative infringement theories.
Key takeaways
- US 11,608,343 claim 1 is a genus covering Formula (I) compounds with substituent permutations across R1, R2, R3, R4, Q, Z, and R5, plus salts and stereoisomers, excluding only the edge-case where R1=H and R2=H.
- Dependent claims 2-10 lock in substitution profiles including F/Cl at R1 and CH3, C≡CH, OCH3 at R1, plus R2=Cl and parameterized R4 subclasses.
- Composition claims 12-13 broadly cover pharmaceutical compositions and co-active combinations where the co-active is classified broadly as cytostatic or cytotoxic.
- Method-of-use claim 14 covers treatment of a defined oncology list; avoiding it requires either an active outside claim 1 or use outside those listed cancers.
- The overall claim set follows a layered protection strategy: genus + redundant dependent embodiments + fallback enumerated/structure-specific compounds.
FAQs
1) What is the single most important element for claim 1 infringement mapping?
The accused compound must satisfy the full Formula (I) parameterization, including the proviso requiring at least one of R1 and R2 is not H.
2) Do salts and stereoisomers broaden infringement exposure?
Yes. Claim 1 expressly includes “pharmaceutically acceptable salt or stereoisomer,” so competitors must assess salt forms and stereochemical variants.
3) Can a competitor avoid the composition claims by changing excipients?
Not if the composition still includes a therapeutically effective amount of the claim 1 compound; claim 12 is excipient-flexible.
4) How does the oncology indication list affect design-around?
Claim 14 is limited to cancers in its group listing; using the same compound for an indication outside that list is the main indication-based avoidance route.
5) Which claim type is usually most enforceable: genus or structure-specific?
Structure-specific claims (where fully specified) often become the most straightforward in claim-to-product mapping, but claim 1 is still the broadest coverage anchor.
References
- United States Patent 11,608,343. (Patent text and claim excerpts provided in prompt).
